New gel could stop bleeding during heart surgery
NCT ID NCT06511778
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This trial tests a gel-like hemostatic agent called Hemoblast bellows to reduce bleeding during heart surgery. About 60 adults undergoing open-heart surgery will receive the gel on their breastbone. Researchers will measure bleeding scores and chest tube output to see if it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Hemoblast bellows (a topical hemostatic agent)
- What this could lead to
- If it works, this could provide a simple way to control bleeding during heart surgery, reducing complications and recovery time.
- What could go wrong
- This is a small, early-phase trial with only 60 participants. The results may not apply to all patients, and the agent may not significantly reduce bleeding.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXCESSIVE BLEEDING DURING SURGERY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
WakeMed Health and Hospitals
RECRUITINGRaleigh, North Carolina, 27610, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••